Previous 10 | Next 10 |
Springfield, Oregon--(Newsfile Corp. - February 27, 2024) - Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("Silo" or "the Company"), a leading global psychedelics wellness company, announces that the Letter of Intent (LOI) to acquire NUGL (Kaya Group in Jamaica) previously announced...
SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...
International Zeolite Corp. (IZCFF) is expected to report for Q2 2024 International Stem Cell Corporation (ISCO) is expected to report for Q4 2023 Zivo Bioscience Inc. (ZIVO) is expected to report for Q4 2023 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4...
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today provided a positive update on SP-26, its novel time-released, dose-controlle...
Initial indications target fibromyalgia and chronic pain Loaded and encapsulated drug maintains structural stability as implantable treatment SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a dev...
Verde Clean Fuels Inc. (VGAS) is expected to report for Q4 2023 Pioneer Bancorp Inc. (PBFS) is expected to report for Q2 2024 Equity Commonwealth of Beneficial Interest (EQC) is expected to report $0.27 for Q4 2023 monday.com Ltd. (MNDY) is expected to report $-0.31 for Q4 2023 As...
Silo Pharma Inc. (SILO) is expected to report for Q4 2023
Silo Pharma (NASDAQ: SILO) , a developmental stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced updates for its strategic 2024 focus for its clinical pipeline. According to the announceme...
Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the ...
2024-01-25 08:25:44 ET More on Pre-market losers & stocks. LG Display Co Ltd (LPL) Q4 2023 Earnings Call Transcript LG Display: It Is The Long-Term Picture That Is Giving People Pause Silo Pharma stock rises after inking exclusive license deal with Medspray Pharm...
News, Short Squeeze, Breakout and More Instantly...
SILO Pharma Inc Company Name:
SILO Stock Symbol:
OTCMKTS Market:
SARASOTA, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutica...
Silo Pharma (NASDAQ: SILO) , a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its planned attendance at a hybrid public meeting on June 27, 2024. The meeting ...
SARASOTA, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic tr...